Ferrostatin-1 specifically targets mitochondrial iron-sulfur clusters and aconitase to improve cardiac function in...

Area of Science:

• Cardiovascular Research
• Mitochondrial Biology
• Cell Death Mechanisms

Background:

• Ferroptosis, an iron-dependent cell death, is implicated in ischemic heart disease.
• Sirtuin 3 (SIRT3) is linked to ferroptosis and cardiac fibrosis.
• Mitochondrial dysfunction is a key factor in heart failure.

Purpose of the Study:

• To investigate if SIRT3 knockout in cardiomyocytes (SIRT3cKO) promotes mitochondrial ferroptosis.
• To determine if blocking ferroptosis can ameliorate mitochondrial dysfunction in the context of SIRT3 deficiency.
• To explore the role of SIRT3 as a mitochondrial deacetylase in ferroptosis.

Main Methods:

• Comparative analysis of mitochondrial and cytosolic fractions from SIRT3cKO and SIRT3loxp mice.
• Echocardiography to assess cardiac function (EF% and FS%).
• Analysis of protein acetylation, key ferroptosis regulators (GPX4, frataxin, aconitase), and oxidative stress markers (4-hydroxynonenal).
• Treatment with ferroptosis inhibitor ferrostatin-1 (Fer-1) in SIRT3cKO mice.

Main Results:

• SIRT3cKO mice exhibited heart failure with reduced EF% and FS%.
• Loss of SIRT3 led to increased mitochondrial acetylation, including acetylated p53, and decreased mitochondrial GPX4, frataxin, and aconitase.
• Ferrostatin-1 treatment improved cardiac function, increased GPX4 and aconitase, and restored mitochondrial integrity in SIRT3cKO mice.

Conclusions:

• SIRT3 is a critical mitochondrial deacetylase regulating ferroptosis.
• Inhibition of ferroptosis ameliorates cardiac dysfunction by targeting mitochondrial aconitase and iron-sulfur clusters.
• Blocking mitochondrial ferroptosis presents a potential therapeutic strategy for mitochondrial cardiomyopathies.